SGK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL420903	0.79	5/20
SCHEMBL421605	0.79	5/20
SCHEMBL423038	0.78	5/20
SCHEMBL422816	0.69	5/20
SCHEMBL420858	0.63	5/20
SCHEMBL414672	0.41	5/20
SCHEMBL419765	1.00	4/20
SCHEMBL422239	1.00	4/20
SCHEMBL422640	1.00	4/20
SCHEMBL422778	1.00	4/20
SCHEMBL423838	0.82	4/20
SCHEMBL423819	0.82	4/20
SCHEMBL420207	0.79	4/20
SCHEMBL424914	0.78	4/20
SCHEMBL423362	0.78	4/20
SCHEMBL425759	0.67	4/20
SCHEMBL423375	0.66	4/20
SCHEMBL421858	0.63	4/20
SCHEMBL425390	0.61	4/20
SCHEMBL425161	0.58	4/20

Clinical trials — most relevant to SGK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	PHASE2	UNKNOWN
Glucocorticoid Induced Whole Body Catabolisme	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Study of CS231295 in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Rehabilitation Program in Patients With Acromegaly	nan	UNKNOWN
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SGK2 binder may also engage these)

Protein	Name	Similarity
Q8R4U9	—	1.000	Q8R4U9 →
Q9QZS5	—	1.000	Q9QZS5 →
Q6U1I9	—	0.991	Q6U1I9 →
Q9WVC6	—	0.990	Q9WVC6 →
SGK1	Serine/threonine-protein kinase Sgk1	0.987	landscape →
Q9XT18	—	0.987	Q9XT18 →
Q9ERE3	—	0.985	Q9ERE3 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.985	landscape →
Q922R0	—	0.985	Q922R0 →
Q5Q0U5	—	0.985	Q5Q0U5 →
PRKX	cAMP-dependent protein kinase catalytic subunit PRKX	0.985	landscape →
Q6GPN6	—	0.985	Q6GPN6 →
Q8R4V0	—	0.984	Q8R4V0 →
Q6PFQ0	—	0.984	Q6PFQ0 →
Q5R7A7	—	0.983	Q5R7A7 →
Q63531	—	0.983	Q63531 →
A7MB74	—	0.983	A7MB74 →
Q06226	—	0.982	Q06226 →
SGK3	Serine/threonine-protein kinase Sgk3	0.982	landscape →
Q7ZTW4	—	0.982	Q7ZTW4 →
Q4R633	—	0.982	Q4R633 →
P54644	—	0.981	P54644 →
Q6GLY8	—	0.981	Q6GLY8 →
P05128	—	0.981	P05128 →
P63319	—	0.981	P63319 →
P63318	—	0.981	P63318 →
Q16974	—	0.981	Q16974 →
P06245	—	0.980	P06245 →
Q4R4U2	—	0.980	Q4R4U2 →
A8XJQ6	—	0.980	A8XJQ6 →